Should You Buy TScan Therapeutics Inc (TCRX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Sell
Latest Price
1.020
1 Day change
-1.92%
52 Week Range
2.670
Analysis Updated At
2026/01/30
TCRX is not a good buy right now for an impatient investor. The trend is clearly bearish (moving averages stacked bearishly and MACD weakening), there are no Intellectia buy signals today, and Wall Street sentiment has deteriorated due to program delays and fewer near-term catalysts. With downside-biased pattern odds over the next month, the risk/reward is unfavorable for an immediate entry.
Technical Analysis
Price/Trend: Bearish trend with SMA_200 > SMA_20 > SMA_5 (persistent downtrend). Momentum: MACD histogram -0.0138 and negatively expanding, signaling bearish momentum is strengthening. RSI_6 at 22.275 indicates the stock is very weak/near oversold conditions (possible short-term bounce risk), but oversold alone is not a buy signal here given the broader downtrend. Levels: Pivot 1.104 is overhead (current post-market ~1.04), implying the stock is below a key pivot. Immediate support S1 1.026 then S2 0.978; resistance R1 1.183 then R2 1.231. Quant/Pattern read-through: Similar-pattern stats imply a likely -8.55% over the next month, reinforcing the bearish setup.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
Hedge funds are buying (reported buying amount up 12447.81% QoQ), which can provide incremental support. Very weak/near-oversold RSI can allow for sharp short-term rebounds. Latest quarter showed strong YoY revenue growth (though from a low base).
Neutral/Negative Catalysts
Analyst downgrades and lower price targets tied to delayed catalysts: pivotal TSC-101 study initiation pushed to Q2 FY26 and solid-tumor program paused, reducing near-term upside drivers. No news/catalysts in the past week. Technicals remain decisively bearish (downtrend + deteriorating MACD). Pattern-based expectation suggests negative 1-month performance (-8.55%).
Financial Performance
Latest quarter: 2025/Q3. Revenue increased to $2.511M (+139.37% YoY), but profitability remains deeply negative: net income -$35.71M (loss improved 19.48% YoY) and EPS -0.28 (improved 12% YoY). Gross margin listed at 100 (flat YoY), consistent with the company still being in a development-stage profile where operating expenses drive losses. Overall: improving YoY trends, but still cash-burn/early-stage dynamics with limited near-term fundamental inflection indicated in the data provided.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings and targets moved down materially. Morgan Stanley downgraded to Equal Weight from Overweight and cut its base-case target range to $1-$5 (from $7-$13) due to reduced visibility and trial timing pushed out to Q2 FY26. BTIG downgraded to Neutral from Buy after the company prioritized hematologic malignancy and paused solid-tumor enrollment, citing fewer near-term catalysts and a later assumed approval timeline. Needham maintained Buy but reduced its target to $6 from $9, noting ASH abstract data suggesting some loss of activity vs. prior year. Wall Street pros: TSC-101 still seen as potentially meaningful in a high-need setting. Wall Street cons: delayed pivotal timeline, program narrowing, less catalyst density, and reduced confidence/visibility—net negative near-term.
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.5 USD with a low forecast of 3 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.5 USD with a low forecast of 3 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.040
Low
3
Averages
5.5
High
7
Current: 1.040
Low
3
Averages
5.5
High
7
Morgan Stanley
Maxwell Skor
Overweight -> Equal Weight
downgrade
AI Analysis
2025-11-13
Reason
Morgan Stanley
Maxwell Skor
Price Target
AI Analysis
2025-11-13
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics to Equal Weight from Overweight. The firm's new base case price target is now $1-$5 vs. $7-$13 prior. After the company's recent strategic prioritization update, the firm plans to remain on the sidelines until there is greater visibility on near-term catalysts, the analyst tells investors in a research note. This change reflects that the pivotal TSC-101 study is now expected to initiate in Q2 of FY26 vs. prior forecast of the second half of FY25, the firm added.
BTIG
Justin Zelin
Buy -> Neutral
downgrade
2025-11-04
Reason
BTIG
Justin Zelin
Price Target
2025-11-04
downgrade
Buy -> Neutral
Reason
BTIG analyst Justin Zelin downgraded TScan Therapeutics to Neutral from Buy without a price target following the company's decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TCRX
